Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

NCT03748186 is registered in ClinicalTrials.gov with Sutro Biopharma, Inc. as lead sponsor.

NCT NCT03748186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03748186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Lead sponsor
Sutro Biopharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 1, 2019
Completion date
June 4, 2024
Enrollment
136 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, endometrioid adenocarcinoma, fallopian tube cancer, ovarian cancer, ovarian carcinoma, ovary cancer, primary peritoneal carcinoma